Rossing P, Agarwal R, Anker SD, et al. - According to this exploratory subgroup analysis, finerenone lowers urine albumin-to-creatinine ratio (UACR) in patients with or without glucagon-like peptide-1 receptor agonist (GLP-1RA) use at baseline, and the effects on renal and CV outcomes are consistent regardless of GLP-1RA use.

• Patients with T2D who had a UACR of 30–5,000 mg/g and an estimated glomerular filtration rate (eGFR) of 25–< 75 mL/min per 1.73 m ² receiving optimized renin-angiotensin system inhibition were randomly assigned to finerenone or placebo.

• Overall, 394 (6.9%) of the 5,674 patients studied received GLP-1RAs at baseline.

• Finerenone reduced UACR with or without baseline GLP-1RA use; the least-squares ratio was 0.63 with GLP-1RA use and 0.69 without GLP-1RA use.

• In addition, finerenone significantly reduced the primary kidney outcomes (time to kidney failure, sustained decrease in eGFR ≥ 40% from baseline, or renal death) and key secondary CV outcomes (time to CV death, non-fatal myocardial infarction, non-fatal stroke, or hospitalization for heart failure) compared with placebo, with no clear difference due to GLP-1RA use at baseline or any time during the trial.

• Finerenone's safety profile was comparable across subgroups.